CareLit Fachartikel
Acquired resistance in NSCLC with EGFR mutation treated with TKI's: Single center experience and treatment outcome
F Griesinger, V Halbfass, C Hallas, RP Henke, M Falk, A Lüers, M Tiemann · Pneumologie · 2014 · Heft 02
Dokument
1113023
CareLit-ID
Jahr
2014
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Background: Acquired resistance in NSCLC with activating EGFR mutations has been defined by Jackman et al. The molecular mechanisms have been studied in small series of patients: in about 50% of cases, T790 M mutation confers acquired resistance, in 25% c-Met amplification. Other as of yet unknown mechanisms might also play a role. Here we present the acquired resistance mechanisms in a cohort of 16 patients (out of 33 pts.) with activating EGFR mutations treated with TKI and identified at our center. Treatment methods and outcome are also described. Methods: 161 consecutive patients (s. abstract Halbfass et al.…
Schlagworte
Afatinib
Tumor
Treatment Outcome
Crizotinib
Cetuximab
After
Pneumologie
